Answers are grounded in this paper and cite their sources.
The management of anaemia in chronic kidney disease (CKD) patients is a complex, multifaceted process reliant on the administration of exogenous erythropoiesis stimulating agents (ESAs) and iron supplements to ensure the adequate production of viable . Recommended best practice guidelines should be adhered to in order to ensure favourable treatment outcomes whilst the risks often associated with ESA therapy. A paucity in readily available, accurate data makes quantifying the extent which renal anaemia affects our population and how it is managed challenging, however it is expected to follow international . Novel preparations for treating renal anaemia are currently in the clinical trial phase, therefore the potential benefits and risks yet to be confirmed.
No takes yet. Share an insight, caveat, or question.
EL Kok (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: